184 related articles for article (PubMed ID: 22008147)
1. Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits.
Stella B; Arpicco S; Rocco F; Burgalassi S; Nicosia N; Tampucci S; Chetoni P; Cattel L
Eur J Pharm Biopharm; 2012 Jan; 80(1):39-45. PubMed ID: 22008147
[TBL] [Abstract][Full Text] [Related]
2. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections.
Katragadda S; Gunda S; Hariharan S; Mitra AK
Int J Pharm; 2008 Jul; 359(1-2):15-24. PubMed ID: 18472234
[TBL] [Abstract][Full Text] [Related]
3. Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium.
Anand BS; Katragadda S; Nashed YE; Mitra AK
Curr Eye Res; 2004; 29(2-3):153-66. PubMed ID: 15512962
[TBL] [Abstract][Full Text] [Related]
4. In vivo ocular pharmacokinetics of acyclovir dipeptide ester prodrugs by microdialysis in rabbits.
Anand BS; Katragadda S; Gunda S; Mitra AK
Mol Pharm; 2006; 3(4):431-40. PubMed ID: 16889437
[TBL] [Abstract][Full Text] [Related]
5. Synergistic penetration of ethosomes and lipophilic prodrug on the transdermal delivery of acyclovir.
Zhou Y; Wei YH; Zhang GQ; Wu XA
Arch Pharm Res; 2010 Apr; 33(4):567-74. PubMed ID: 20422366
[TBL] [Abstract][Full Text] [Related]
6. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits.
Attia IA; El-Gizawy SA; Fouda MA; Donia AM
AAPS PharmSciTech; 2007 Dec; 8(4):E106. PubMed ID: 18181527
[TBL] [Abstract][Full Text] [Related]
7. Comparison of liposome-encapsulated acyclovir with acyclovir ointment: ocular pharmacokinetics in rabbits.
Chetoni P; Rossi S; Burgalassi S; Monti D; Mariotti S; Saettone MF
J Ocul Pharmacol Ther; 2004 Apr; 20(2):169-77. PubMed ID: 15117573
[TBL] [Abstract][Full Text] [Related]
8. Bioadhesive microspheres for ophthalmic administration of acyclovir.
Genta I; Conti B; Perugini P; Pavanetto F; Spadaro A; Puglisi G
J Pharm Pharmacol; 1997 Aug; 49(8):737-42. PubMed ID: 9379347
[TBL] [Abstract][Full Text] [Related]
9. Interaction of acyclovir and its squalenoyl-acyclovir prodrug with DMPC in monolayers at the air/water interface.
Sarpietro MG; Rocco F; Micieli D; Ottimo S; Ceruti M; Castelli F
Int J Pharm; 2010 Aug; 395(1-2):167-73. PubMed ID: 20635474
[TBL] [Abstract][Full Text] [Related]
10. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea.
Anand B; Nashed Y; Mitra A
Curr Eye Res; 2003; 26(3-4):151-63. PubMed ID: 12815543
[TBL] [Abstract][Full Text] [Related]
11. Self-assembled drug delivery systems. 1. Properties and in vitro/in vivo behavior of acyclovir self-assembled nanoparticles (SAN).
Jin Y; Tong L; Ai P; Li M; Hou X
Int J Pharm; 2006 Feb; 309(1-2):199-207. PubMed ID: 16377106
[TBL] [Abstract][Full Text] [Related]
12. Conjugation of squalene to acyclovir improves the affinity for biomembrane models.
Sarpietro MG; Micieli D; Rocco F; Ceruti M; Castelli F
Int J Pharm; 2009 Dec; 382(1-2):73-9. PubMed ID: 19686827
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of sponge-like acyclovir ocular minitablets.
Refai H; Tag R
Drug Deliv; 2011 Jan; 18(1):38-45. PubMed ID: 20804440
[TBL] [Abstract][Full Text] [Related]
14. Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS.
Dias C; Nashed Y; Atluri H; Mitra A
Curr Eye Res; 2002 Oct; 25(4):243-52. PubMed ID: 12658558
[TBL] [Abstract][Full Text] [Related]
15. Transcorneal permeation of L- and D-aspartate ester prodrugs of acyclovir: delineation of passive diffusion versus transporter involvement.
Majumdar S; Hingorani T; Srirangam R; Gadepalli RS; Rimoldi JM; Repka MA
Pharm Res; 2009 May; 26(5):1261-9. PubMed ID: 18839288
[TBL] [Abstract][Full Text] [Related]
16. Aqueous nanomicellar formulation for topical delivery of biotinylated lipid prodrug of acyclovir: formulation development and ocular biocompatibility.
Vadlapudi AD; Cholkar K; Vadlapatla RK; Mitra AK
J Ocul Pharmacol Ther; 2014 Feb; 30(1):49-58. PubMed ID: 24192229
[TBL] [Abstract][Full Text] [Related]
17. A new homodimer of aciclovir as a prodrug with increased solubility and antiviral activity.
Brandi G; Rossi L; Schiavano GF; Millo E; Magnani M
Int J Antimicrob Agents; 2009 Aug; 34(2):177-80. PubMed ID: 19394201
[TBL] [Abstract][Full Text] [Related]
18. Novel nanoparticles made from amphiphilic perfluoroalkyl alpha-cyclodextrin derivatives: preparation, characterization and application to the transport of acyclovir.
Ghera BB; Perret F; Chevalier Y; Parrot-Lopez H
Int J Pharm; 2009 Jun; 375(1-2):155-62. PubMed ID: 19481701
[TBL] [Abstract][Full Text] [Related]
19. Targeted lipid based drug conjugates: a novel strategy for drug delivery.
Vadlapudi AD; Vadlapatla RK; Kwatra D; Earla R; Samanta SK; Pal D; Mitra AK
Int J Pharm; 2012 Sep; 434(1-2):315-24. PubMed ID: 22692074
[TBL] [Abstract][Full Text] [Related]
20. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R
Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
